Focal segmental glomerulosclerosis is a type of non-vascular form of non-neoplastic, non-cancerous carotid artery disease. This disease is also known as 'glycation' because it leads to the glycation of the internal walls of the carotid arteries (these are the arteries that supply oxygen-rich blood to the brain). It is the result of a breakdown in the process of glycolysis, the rate-limiting process in glycolysis in the body. Due to the nature of the disease and the extent of its effects, the management of this condition must be done early and effectively.
This neurological disease can be difficult to diagnose as it is non-specific and frequently associated with other medical conditions such as hyperlipidemia or hypertension. Therefore, the major diagnostic challenge involves the use of protein assays and enzyme assays to determine whether protein levels are within normal limits in the patient's blood, thereby enabling the physician to make a definitive diagnosis. Due to these factors, focal segmental glomerulosclerosis is often difficult to manage and sometimes even to diagnose. There are two main types of focal segmental glomerulosclerosis: idiopathic focal segmental glomerulosclerosis and non-idiopathic focal segmental glomerulosclerosis.
In idiopathic focal segmental glomerulosclerosis, the main indicator of disease is the accumulation of fat in the intervertebral disk, which causes severe pressure on the kidneys, causing painful kidney stones or other complications. Non-idiopathic focal segmental glomerulosclerosis, by contrast, does not usually result in painful kidney stones or other symptoms. The key to treating this form of this condition is targeting the primary cause, which is disease-induced protein deficiency (DIP). Patients diagnosed with idiopathic focal segmental glomerulosclerosis typically respond to standard medications with great success. This is true even for patients whose disease has progressed from the very first stages.
Tags:
Blogs